ARTICLE | Company News
Immunomedics, Nycomed deal
January 25, 2010 8:00 AM UTC
Immunomedics received a $5 million milestone payment from Nycomed under a 2008 deal granting Nycomed exclusive, worldwide rights to develop subcutaneous veltuzumab for non-cancer indications. The pay...